A vital safety-net program

Blog

The exorbitant cost of many prescription drugs threatens providers’ ability to provide life-saving medications for millions of Americans.

That is why the 340B Drug Pricing Program, which provides discounts on drugs to some health care providers who serve large numbers of low-income and uninsured... read more

Topic: Access and Coverage
Tags: 340B, access

Preserve the 340B program

Blog

Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system.

One program that has a 25-year track record of improving access to medications and health care services for people in vulnerable communities... read more

Topic: Advocacy and Public Policy
Tag: 340B

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

340B Proposals Would Jeopardize Hospitals' Ability to Serve Vulnerable Patients

Blog

The 340B Drug Pricing Program has a strong track record of helping to combat high prescription drug prices and increase access to vital medicines and comprehensive health care services for our nation’s most vulnerable individuals.

However, we are concerned that recent policy changes proposed by the... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, drug prices

GAO Report Misses Mark on 340B Program

Blog

A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities.... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access

AHA responds to latest effort by pharmaceutical industry to disparage 340B program

Blog

A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.

For more than 20 years, the 340B Drug Pricing Program has provided financial relief from... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access

Hospital Priorities for the New Congress

Blog

The newly-sworn-in 114th Congress kicked off legislating on a slew of topics and priorities. Similarly, the American Hospital Association is advocating on Capitol Hill for issues affecting the nation’s hospitals. Since the country is in the midst of football playoffs, we will tackle these hospital... read more

Topic: Advocacy and Public Policy
Tags: 340B, site neutral payment, RACs

Setting the Record Straight on 340B

Blog

A new report by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.

For more than 20 years, the 340B Drug Pricing Program has provided financial relief from high... read more

Topic: Access and Coverage
Tag: 340B

Keyword Search

Date